Clinical services revenues rose 56 percent to $92.6 million while pharma services grew 26 percent to $12.1 million.
The company said it anticipates that more than 60 million Medicare beneficiaries will be covered for the ExoDx Prostate IntelliScore (EPI) test on Dec. 1.
Total revenues for the quarter were $2.93 billion, up from $2.83 billion in Q3 2018, and above the consensus Wall Street estimate of $2.91 billion.
The company's life sciences revenues were up 6 percent while its diagnostics business grew almost 7 percent.
The assay, being developed in partnership with Johnson & Johnson, will complement computed tomography imaging by combining 26 genes and clinical variables for lung cancer detection.
The company delivered organic growth across its four business segments and raised its revenue and earnings guidance for the year.
For the three months ended Sept. 30, the firm reported total revenues of $31.0 million, beating analysts' average estimate of $30.1 million.
Revenues of $1.96 billion for the third quarter were up from $1.89 billion in Q3 last year and beat the consensus Wall Street estimate of $1.94 billion.
While clinical lab product revenues were flat year over year, point-of-care sales spiked 29 percent on higher HIV test sales in Africa.
The company's revenues were driven by its centralized and point-of-care solutions as well as its molecular diagnostics business, both rising in the single digits.